Dexcom EVP Coleman sells 9,823 shares under plan

Dexcom Inc. executive Jon Coleman reported open-market sales of company stock under a pre-arranged trading plan.

Rhea-AI Filing Summary

Dexcom Inc. executive Jon Coleman reported open-market sales of company stock under a pre-arranged trading plan. On June 3, 2026, he sold 4,912 shares of common stock at $73.00 per share. On June 4, 2026, he sold an additional 4,911 shares at $74.13 per share.

These transactions, totaling 9,823 shares, were executed pursuant to a Rule 10b5-1 Plan adopted on March 4, 2026, which is designed to allow orderly, pre-scheduled dispositions. After these sales, Coleman directly held 95,450 shares of Dexcom common stock. A related disclosure notes that this number includes 95,450 unvested restricted stock units, consisting of 43,897 units granted March 8, 2026 vesting through March 8, 2029, and 51,553 units granted May 22, 2025 vesting through May 22, 2029. The filing shows no derivative positions remaining.

Insider Trade Summary 10b5-1

Net Seller: 9,823 shares

Net Sell 2 txns

Insider Coleman Jon

Role EVP, Chief Commercial Officer

Sold 9,823 shs ($723K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,911	$74.13	$364K
Sale	Common Stock	4,912	$73.00	$359K

Holdings After Transaction: Common Stock — 95,450 shares (Direct)

Footnotes (2)

1. F1. On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
2. F2. Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

Key Figures

Shares sold 2026-06-03: 4,912 shares at $73.00 Shares sold 2026-06-04: 4,911 shares at $74.13 Total shares sold: 9,823 shares +5 more

8 metrics

Shares sold 2026-06-03 4,912 shares at $73.00 Open-market sale of common stock

Shares sold 2026-06-04 4,911 shares at $74.13 Open-market sale of common stock

Total shares sold 9,823 shares Combined June 3–4, 2026 sales

Shares held after transactions 95,450 shares Direct holdings following June 4, 2026 sale

Unvested RSUs total 95,450 units Unvested restricted stock units included in holdings

RSUs granted March 8, 2026 43,897 units Vest through March 8, 2029

RSUs granted May 22, 2025 51,553 units Vest through May 22, 2029

10b5-1 plan adoption date March 4, 2026 Plan governing the reported stock sales

Key Terms

Rule 10b5-1 Plan, open-market sale, restricted stock units, unvested, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted stock units financial

"Included in this number are 95,450 unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

unvested financial

"Included in this number are 95,450 unvested restricted stock units"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Dexcom (DXCM) report for Jon Coleman?

Dexcom EVP and Chief Commercial Officer Jon Coleman reported two open-market stock sales totaling 9,823 shares of common stock in early June 2026, according to the Form 4 insider trading report.

At what prices did Jon Coleman sell Dexcom (DXCM) shares?

Jon Coleman sold 4,912 Dexcom shares at $73.00 on June 3, 2026 and 4,911 shares at $74.13 on June 4, 2026, reflecting typical open-market trading prices during those days.

How many Dexcom (DXCM) shares does Jon Coleman hold after these sales?

After the reported transactions, Jon Coleman directly holds 95,450 Dexcom shares. A related disclosure states this number includes 95,450 unvested restricted stock units scheduled to vest over multiple years through 2029.

Were Jon Coleman’s Dexcom (DXCM) stock sales pre-planned under Rule 10b5-1?

Yes. The filing states that on March 4, 2026, Jon Coleman adopted a Rule 10b5-1 trading plan, and the June 3–4, 2026 stock sales were executed pursuant to that pre-arranged plan.

What equity awards are disclosed for Jon Coleman at Dexcom (DXCM)?

The filing notes 95,450 unvested restricted stock units, including 43,897 units granted March 8, 2026 vesting through March 8, 2029, and 51,553 units granted May 22, 2025 vesting through May 22, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Jon

(Last) (First) (Middle)

6430 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		S		4,912(1)	D	$73	100,361	D
Common Stock	06/04/2026		S		4,911(1)	D	$74.13	95,450(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

2. Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Jon Coleman	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)